GnRH analogues in IVF and monitoring embryo development.

GnRH analogues for ovarian stimulation and embryo quality: Monitoring embryo development using a time lapse incubator.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON27852

Enrollment

Registered

2011-12-21

Start date

2017-03-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IVF, ovarian stimulation, preimplantation embryo development, EmbryoScope

Interventions

Randomization to one of two routinely applied ovarian stimulation protocols: 1. GnRH agonist long stimulation protocol with a daily dose of 150 IU recombinant FSH

2. GnRH antagonist stimulation protocol starting with administration of 150 IU r-FSH on cycle day 2 or 5, with GnRH antagonist treatment start on stimulation day 1.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Female age 15*10˄6, progressively motile sperm >32%, so with a VCM ≥ 7,2) 4. Standard indication for IVF 5. Undergoing first or second IVF cycle 6. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Indication for ICSI 2. Endometriosis 3. Expected poor response 4. One previous IVF treatment not resulting in embryo transfer 5. Medical contra indication for pregnancy or IVF treatment 6. Relevant systemic disease

Design outcomes

Primary

Measure	Time frame
Morphokinetic parameters of embryo development.	—

Secondary

Measure	Time frame
1. Fertilization rate; 2. Embryo morphology; 3. Implantation rates; 4. Ongoing pregnancy rates.	—

Contacts

Public ContactJoop S.E. Laven

P.O.Box 2040

j.laven@erasmusmc.nl+31 (0)10 7033760

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)